Grant Elise Mathilde Fund & LUF: Using virus to kill bacteria: design of innovative phage-antibiotic combination treatments to combat antimicrobial resistance
Phage therapy is a novel yet unmatured therapeutic approach in the face of the crisis of antimicrobial resistance (AMR). Dr. Tingjie Guo received a grant from the Elise Mathilde Fund and the LUF to develop innovative phage-antibiotic combination treatment strategy for combating AMR.
AMR-associated bacterial infections are a major threat to public health. Bacteriophages (or phages) are emerging as promising alternative treatment of AMR-associated infections. Phages are viruses that infect, replicate, and ultimately kill bacterial cells. However, there is currently a lack of strong rationale for designing optimal dosing schedules for phage therapy. Dr. Guo and his colleagues will perform research through an integrative approach that bridges experimental and computational methods to develop rational phage-antibiotic combination treatment strategy. This project will be an important step to support the further optimal use of phage therapy in clinical care. Dr. Guo also hopes that the results of this project will help him to be successful in applying for follow-up grants.
